Middle East News Dispatch
SEE OTHER BRANDS

The most trusted news from the Middle East

Middle East News Dispatch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Dispatch.

Press releases published on June 17, 2025

TDG Gold Announces Acquisition of Anyox Copper and C$25 Million Bought Deal Private Placement

TDG Gold Announces Acquisition of Anyox Copper and C$25 Million Bought Deal Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) -- TDG Gold Corp (TSXV: TDG, OTCQX:TDGGF) (the “Company” or “TDG”) is pleased to announce that it …

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial …

Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide

Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide

BOSTON and SHANGHAI, June 17, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that …

Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS

Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS

CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to zagociguat for the treatment of MELAS (Mitochondrial Encephalomyopathy, Lactic …

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty …

Koryx Copper Provides Project Development Update for the Haib Copper Project, Southern Namibia

Koryx Copper Provides Project Development Update for the Haib Copper Project, Southern Namibia

Highlights Metallurgical testwork program with encouraging preliminary results including 89% average flotation recovery from 120-150µm grind size producing clean concentrate with grade of 20-25% Cu. Pre-concentration and heap leach testwork ongoing with …

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3232 …

Material Update on Off-Market Takeover by Bastion Mining

Material Update on Off-Market Takeover by Bastion Mining

TORONTO, Canada, June 17, 2025 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) today provides an important update in relation to the off-market takeover offer by Bastion Mining Pte. Ltd. UEN 202512367N (Bastion) to acquire …

Surge Copper Reports Excellent Metallurgical Results Supporting Pre-Feasibility Advancement at Berg Project

Surge Copper Reports Excellent Metallurgical Results Supporting Pre-Feasibility Advancement at Berg Project

Locked cycle tests exceed 90% copper and molybdenum recoveries and confirm clean final products with high separation efficiency Vancouver, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) …

NexGold Receives Notice of Completion on Industrial Approval from the Government of Nova Scotia for the Goldboro Gold Project

NexGold Receives Notice of Completion on Industrial Approval from the Government of Nova Scotia for the Goldboro Gold Project

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- NexGold Mining Corp. (TSXV: NEXG; OTCQX: NXGCF) (“NexGold” or the “Company”) is pleased to announce that the Government of Nova Scotia has deemed the Company’s application for an Industrial Approval of a Surface …

OROCO ANNOUNCES PRIVATE PLACEMENT

OROCO ANNOUNCES PRIVATE PLACEMENT

VANCOUVER, Canada, June 17, 2025 (GLOBE NEWSWIRE) -- Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) of up to 5,000,000 units of the Company (each, a “Unit”) …

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE …

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with complete response remained in complete response at ≥ 6 …

Prime Announces Completion of June Warrant Exercise

Prime Announces Completion of June Warrant Exercise

VANCOUVER, British Columbia, June 17, 2025 (GLOBE NEWSWIRE) -- Prime Mining Corp. (“Prime” or the “Company”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) announces that 97% of its $1.10 warrants due June 12, 2025 have been exercised, which, including the …

Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant

Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant

GROTON, Conn., June 17, 2025 (GLOBE NEWSWIRE) -- Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service